Orum takes $8M in Se­ries A; Twist bags $27M in ven­ture fi­nanc­ing

→Dae­jeon, Ko­rea-based Orum Ther­a­peu­tics closed its Se­ries A fund­ing with $8 mil­lion from In­ter­Vest, KB In­vest­ment (KBIC)/Solidus In­vest­ment, and LB In­vest­ment. “We were im­pressed with Orum’s cell-pen­e­trat­ing an­ti­body plat­form, which can trans­form an­ti­bod­ies to ef­fec­tive­ly tar­get un­drug­gable cy­toso­lic tar­gets, with­out chem­i­cal con­ju­ga­tion and with tar­get cell speci­fici­ty,” said Yeo Jung Moon, in­vest­ment di­vi­sion di­rec­tor at In­ter­vest.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER